IGF1R and adrenal cortex carcinoma: In conclusion, the present study describes the IGF pathway in ACC and explores the response to the combined treatment with the dual IGF1-/IR inhibitor linsitinib, and mTOR inhibitors in in-vitro models of ACC, demonstrating that human ACC express IGF2R and IRA which, in addition to IGF2 and its receptor IGF1R, might modulate the IGFs effects and linsitinib and mTOR inhibitors have additive antiproliferative effects.